Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Several studies have demonstrated that approximately one-half of patients with chronic myeloid leukemia (CML) who receive treatment with tyrosine kinase inhibitors (TKIs) and achieve and maintain a deep molecular response (DMR) are able to successfully discontinue therapy. In patients who have a molecular relapse, a DMR is rapidly regained upon treatment re-initiation.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer

Title: Cancer

Publisher: Wiley-Blackwell

ISSN (Electronic): 1097-0142

ISSN (Print): 0008-543X

Publication date (Electronic): Nov 15 2017

Volume: 123

Issue: 22

Affiliations

[1 ] Hematology Department, Nice University Hospital, Nice, France.

[2 ] Valrose Institute of Biology, National Center for Scientific Research (CNRS) Unit 7277, National Institute of Health and Medical Research (INSERM) Unit 1091, Nice, France.

[3 ] Hematology Department, Lyon University Hospital, Pierre Benite, France.

[4 ] INSERM Unit 1052, Leon Berard Center, Lyon, France.

[5 ] Haematology Department, Bergonie Institute, Bordeaux, France.

[6 ] Haematology and Oncology Department, Hopital A Mignot, INSERM Unit 1173, Versailles, University of Versailles St.-Quentin-Yvelines, France.

[7 ] Adult Hematology Department, INSERM Unit 1160, St. Louis Hospital, Paris, France.

[8 ] Hematology Laboratory, Henri-Mondor Hospital, Creteil, France.

[9 ] Hematology Department, Brabois University Hospital, Vandoeuvre-les-Nancy, France.

[10 ] Hematology Department, Toulouse-Oncopole University Cancer Institute, Toulouse, France.

[11 ] Blood Disorder Department, Angers University Hospital, Angers, France.

[12 ] Adult Hematology Department, Rennes University Hospital, Rennes, France.

[13 ] Hematology Department, Brest University Hospital, Brest, France.

[14 ] Blood Disorders Department, Lille University Hospital, Lille, France.

[15 ] Blood Disorders Department, Necker Hospital, Paris-Descartes University, Paris, France.

[16 ] Laboratory of Mammary and Leukemic Oncogenesis, Genetic Diversity, and Resistance to Treatment, INSERM Unit 1218, Bordeaux, France.

Article

DOI: 10.1002/cncr.30885

PubMed ID: 28743166

SO-VID: 0813826a-d6c6-4731-ba1e-cca131bfe20d

History

Keywords: tyrosine kinase inhibitor,chronic myeloid leukemia,hematology,myeloproliferative disorders,therapy discontinuation

Data availability:

Keywords: tyrosine kinase inhibitor, chronic myeloid leukemia, hematology, myeloproliferative disorders, therapy discontinuation

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

Read this article at

Abstract

Related collections

Hematology and Oncology Discovery

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 268

Cited by 38